OTLK vs. INZY, FATE, CYBN, AMRN, ACRS, CDTX, CHRS, HURA, SCPH, and MRSN
Should you be buying Outlook Therapeutics stock or one of its competitors? The main competitors of Outlook Therapeutics include Inozyme Pharma (INZY), Fate Therapeutics (FATE), Cybin (CYBN), Amarin (AMRN), Aclaris Therapeutics (ACRS), Cidara Therapeutics (CDTX), Coherus BioSciences (CHRS), TuHURA Biosciences (HURA), scPharmaceuticals (SCPH), and Mersana Therapeutics (MRSN). These companies are all part of the "pharmaceutical products" industry.
Outlook Therapeutics vs.
Inozyme Pharma (NASDAQ:INZY) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, community ranking, valuation, media sentiment, analyst recommendations, dividends and earnings.
Outlook Therapeutics' return on equity of 0.00% beat Inozyme Pharma's return on equity.
Inozyme Pharma is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks.
Inozyme Pharma presently has a consensus price target of $17.00, indicating a potential upside of 488.24%. Outlook Therapeutics has a consensus price target of $32.73, indicating a potential upside of 1,263.89%. Given Outlook Therapeutics' higher probable upside, analysts plainly believe Outlook Therapeutics is more favorable than Inozyme Pharma.
Outlook Therapeutics received 110 more outperform votes than Inozyme Pharma when rated by MarketBeat users. However, 86.44% of users gave Inozyme Pharma an outperform vote while only 70.93% of users gave Outlook Therapeutics an outperform vote.
88.3% of Inozyme Pharma shares are owned by institutional investors. Comparatively, 11.2% of Outlook Therapeutics shares are owned by institutional investors. 11.2% of Inozyme Pharma shares are owned by insiders. Comparatively, 3.4% of Outlook Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Outlook Therapeutics had 9 more articles in the media than Inozyme Pharma. MarketBeat recorded 9 mentions for Outlook Therapeutics and 0 mentions for Inozyme Pharma. Outlook Therapeutics' average media sentiment score of 0.05 beat Inozyme Pharma's score of 0.00 indicating that Outlook Therapeutics is being referred to more favorably in the news media.
Inozyme Pharma has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.
Summary
Inozyme Pharma beats Outlook Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Outlook Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Outlook Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:OTLK) was last updated on 1/6/2025 by MarketBeat.com Staff
